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Introduction: The human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase (RTK) oncogene is an
attractive therapeutic target for the treatment of HER2-addicted tumors. Although lapatinib, an FDA-approved
small-molecule HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), represents a
significant therapeutic advancement in the treatment of HER2+ breast cancers, responses to lapatinib have not
been durable. Consequently, elucidation of mechanisms of acquired therapeutic resistance to HER-directed
therapies is of critical importance.
Methods: Using a functional protein-pathway activation mapping strategy, along with targeted genomic
knockdowns applied to a series of isogenic-matched pairs of lapatinib-sensitive and resistant cell lines, we now
report an unexpected mechanism of acquired resistance to lapatinib and similar TKIs.
Results: The signaling analysis revealed that whereas HER2 was appropriately inhibited in lapatinib-resistant cells,
EGFR tyrosine phosphorylation was incompletely inhibited. Using a targeted molecular knockdown approach to
interrogate the causal molecular underpinnings of EGFR-persistent activation, we found that lapatinib-resistant cells
were no longer oncogene addicted to HER2-HER3-PI3K signaling, as seen in the parental lapatinib-sensitive cell
lines, but instead were dependent on a heregulin (HRG)-driven HER3-EGFR-PI3K-PDK1 signaling axis. Two FDA-
approved EGFR TKIs could not overcome HRG-HER3-mediated activation of EGFR, or reverse lapatinib resistance.
The ability to overcome EGFR-mediated acquired therapeutic resistance to lapatinib was demonstrated through
molecular knockdown of EGFR and treatment with the irreversible pan-HER TKI neratinib, which blocked HRG-
dependent phosphorylation of HER3 and EGFR, resulting in apoptosis of resistant cells. In addition, whereas HRG
reversed lapatinib-mediated antitumor effects in parental HER2+ breast cancer cells, neratinib was comparatively
resistant to the effects of HRG in parental cells. Finally, we showed that HRG expression is an independent negative
predictor of clinical outcome in HER2+ breast cancers, providing potential clinical relevance to our findings.
Conclusions: Molecular analysis of acquired therapeutic resistance to lapatinib identified a new resistance
mechanism based on incomplete and “leaky” inhibition of EGFR by lapatinib. The selective pressure applied by
incomplete inhibition of the EGFR drug target resulted in selection of ligand-driven feedback that sustained EGFR
activation in the face of constant exposure to the drug. Inadequate target inhibition driven by a ligand-mediated
autocrine feedback loop may represent a broader mechanism of therapeutic resistance to HER TKIs and suggests
adopting a different strategy for selecting more effective TKIs to advance into the clinic.* Correspondence: Wenle.Xia@duke.edu; Neil.Spector@duke.edu
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Members of the human epidermal growth factor recep-
tor (HER) family of transmembrane receptor tyrosine
kinases (HER1/EGFR; HER2; HER3; HER4) and their
respective ligands constitute a robust biologic system
that plays a key role in the regulation of cell-proliferative
growth, survival, and differentiation [1-6]. Ligand-bound
monomeric HER receptors form homo- or heterodimers,
which in turn activate their respective autokinase ac-
tivities, leading to self-phosphorylation of c-terminus
tyrosine residues serving as docking sites for adaptor
proteins that activate downstream growth and survival
signaling cascades [3-6]. HER2, the preferred dimeriza-
tion partner for HER3 and EGFR, amplifies the signal
generated through the dimer receptor complex [4].
HER3, conversely, is transactivated by its dimerization
partner [7]. Importantly, HER3 contains six phospho-
tyrosine binding sites for the p85 subunit of PI3K
(phosphoinositide 3-kinase), the most of all HER family
members [8]. Consequently, HER2-HER3 dimers are po-
tent activators of PI3K signaling, which in breast and
other solid tumors, represents an important oncogenic
signaling unit [9].
Deregulation of HER signaling, which can occur as
a consequence of gene amplification (HER2) or gain-
of-function mutation (EGFR) promotes solid-tumor
oncogenesis. In breast and ovarian cancers, HER2 over-
expression (HER2+) predicts for a poor clinical outcome
[10,11], findings that have prompted the development of
HER2-targeted therapies, including small-molecule tyro-
sine kinase inhibitors (TKIs) designed to block the
autokinase activity of the HER2 receptor. Lapatinib is a
highly selective, small-molecule inhibitor of the HER2
and EGFR tyrosine kinases [12]. It is currently the only
FDA-approved tyrosine kinase inhibitor (TKI) for the
treatment of advanced-stage HER2+ breast cancers [13].
Although lapatinib is considered an equipotent inhibitor
of HER2 and EGFR, based on data from in vitro kinase
assays [14,15], its clinical efficacy to date has been lim-
ited to HER2+ breast cancers [16]. Despite representing
a significant therapeutic advance in the treatment of ag-
gressive HER2+ breast cancers, the clinical efficacy of
lapatinib has been limited by the inevitable development
of therapeutic resistance [13,16]. In this regard, several
mechanisms of acquired therapeutic resistance have
been reported, based primarily on data generated from
preclinical models [17-23]. In contrast to other kinase
inhibitors, in which mutations in the ATP-binding
pocket of the targeted kinase can lead to reactivation of
the targeted protein [24,25], we and others have shown
that HER2 mutation do not appear to play a role in resist-
ance, and that phosphorylation of HER2 remains inhibited
in models of acquired lapatinib resistance [17,22,23]. Fur-
thermore, previous work from our laboratory has shownthat molecular knockdown of HER2 does not reverse
lapatinib resistance, providing additional evidence that re-
sistant cells are no longer dependent on HER2 for survival
[17]. The recent decision to discontinue a lapatinib mono-
therapy treatment arm in the ALTTO study, an ongoing
global phase III clinical trial of adjuvant HER2-targeted
therapies in the treatment of early-stage HER2+ breast
cancers, due to an increased incidence of disease recur-
rence, underscores the need to understand better the re-
sistance conundrum. Elucidating mechanisms of acquired
therapeutic resistance to HER TKIs and kinase inhibitors
in general is therefore of critical importance in the ma-
nagement of kinase-driven diseases.
The tumor-promoting PI3K cell-signaling pathway has
been shown to be persistently activated in models of ac-
quired therapeutic resistance to lapatinib and similar
HER TKIs in class [19,20]. The role of activating PI3KCA
mutations or PTEN loss as a potential explanation for the
persistent activation of PI3K signaling in lapatinib resist-
ance remains controversial [19,26-28]. Here, we show that
acquired therapeutic resistance to lapatinib in models of
HER2+ breast cancer can be mediated by autocrine induc-
tion of the membrane-bound form of the HER3 ligand
heregulin (HRG). Increased expression of full-length HRG
in combination with inadequate inhibition of EGFR phos-
phorylation by lapatinib promotes an HRG-HER3-EGFR-
PI3K signaling axis that contributes not only to lapatinib
resistance, but also to cross-resistance to FDA-approved
EGFR TKIs. These findings could have a significant im-
pact not only on the treatment of HER2- and EGFR-
dependent tumors, but also on relevance to the treatment
of kinase-driven diseases in general.
Methods
Cell culture and reagents
Human breast cancer cell lines BT474, SKBR3, Au565,
and SUM190 were obtained from the American Type
Culture Collection (Manassas, VA, USA). Lapatinib-
resistant cell lines (rBT474, rSKBR3, rAu565, and
rSUM190) were generated and continuously maintained
in 1 μM lapatinib, as previously described [17,18]. The
4G10 anti-phosphotyrosine (p-tyr) antibody was pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Mono-
clonal antibodies to c-HER2 and EGFR were purchased
from Neo Markers (Union City, CA, USA). Phospho-
specific primary antibodies to EGFR (Y992), EGFR
(Y1148), EGFR (Y1173), EGFR (Y1068), and HER3
(Y1197), and PARP cleavage product were obtained from
Cell Signaling (Beverly, MA, USA). Anti-PDK1 antibody
was purchased from R&D Systems (Minneapolis, MN,
USA). Antibodies to phosho-PI3Kp85 (Y508), Akt1/2,
phospho-Akt1/2 (S473), phospho-Akt1/2 (T308), HRG
and siRNA constructs (Akt1/2; PI3K subunits; PKC,
PDK1, SGK, HRG, and control siRNA-A) were purchased
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antibody was from Bethyl (Montgomery, TX, USA).
ADAM17 antibody was purchased from Abcam
(Cambridge, MA, USA). Erlotinib was obtained from
Genentech (South San Francisco, CA, USA). SU11274,
neratinib, and AZD0530 were from Selleck (Houston, TX,
USA). IRDye800 conjugated affinity-purified anti-rabbit
IgG and anti-mouse IgG were purchased from Rockland
(Gilbertsville, PA, USA). Alexa Fluor680 goat anti-rabbit
IgG was obtained from Molecular Probes (Eugene, OR,
USA). NVP-BEZ 235 was obtained from Novartis (Basel,
Switzerland). Lapatinib and gefitinib were purchased from
LC Laboratories (Woburn, CA, USA).
siRNA transfection
Cell transfections were performed in a six-well format
by using 5 μl lipofectamine 2000 (Invitrogen Life Tech-
nologies) in OPTI-MEM I (Invitrogen Life Technologies,
Carlsbad, CA, USA) at 5 × 105 cells per well, with indi-
vidual siRNAs against target proteins, and nonspecific
siRNA (NSC) as controls, as described in the Invitrogen
transfection protocol and in our previous publications
[17,26]. The concentration of siRNA was 100 nM in a
final volume of 2.5 ml. After 16 to 18 hours, the trans-
fection media was removed and replaced with complete
RPMI 1640 supplemented with 1 μM lapatinib for an
additional 48 hours.
SDS-PAGE and Western blot analysis
Details of the methods used for SDS-PAGE and Western
blot analysis have been previously described [17,18,26].
In brief, membranes were incubated with primary anti-
bodies, washed several times in PBS, and then incubated
with a fluorescence-conjugated secondary antibody at a
1:10,000 dilution with 5% try milk in PBS for 60 mi-
nutes, protected from light. After washing in PBS + 0.1%
tween-20, the membranes were scanned and visualized
by using the Odyssey Infrared Imaging System (LI-COR,
Inc., Lincoln, NE, USA).
Cell growth and viability assay
The cell-growth assay was performed in a 96-well plate
format in a final volume of 100 μl/well cell-culture
medium with the cell-proliferation reagent WST-1 from
Roche Diagnostics (Mannheim, Germany). Details of the
WST-1 assay were previously described [17,18,26].
Reverse-phase protein microarray construction and
analysis
Reverse-phase protein microarrays were constructed as
described previously [29]. A list of the antibodies used
in this analysis and their sources are provided (see
Additional file 1). In brief, denatured lysates were spot-
ted onto nitrocellulose-coated glass slides (Whatman,Inc, Sanford, ME, USA) by using a 2470 Arrayer
(Aushon BioSystems, Burlington, MA, USA), outfitted
with 185-μm pins. Each sample was printed in triplicate
as a neat and 1:4 dilution two-point dilution series to en-
sure that one of the points was in the linear dynamic
range of the fluorescence assay. A high and low internal
control for antibody-staining specificity, consisting of ly-
sates derived from pervanadate-treated HeLa cells and
calyculin-treated Jurkat cells were used and spotted onto
every array, along with the experimental samples. Slides
were stored desiccated at −20°C until staining. Blocked
arrays were stained with antibodies on an automated
slide stainer (Dako, Carpinteria, CA, USA) by using the
Catalyzed Signal Amplification System kit (CSA; Dako)
and streptavidin-conjugated IRDye680 (LI-COR Bio-
science, Lincoln, NE, USA) to generate a fluorescence
signal. Each antibody used in the staining process was
previously validated by using Western blot procedure.
Antibodies producing a single band in correspondence
to the molecular weight of interest were considerate vali-
dated and eligible for use in immunostaining. All inten-
sity values were normalized to total protein for each
sample, to account for differences in intensity due solely
to starting lysate concentration variance. The total
amount of protein present in each sample was estimated
through Sypro Ruby Protein Blot Stain (Molecular
Probes) according to the manufacturer’s instructions, as
previously described [29]. All Sypro and immunostained
slides were scanned by using a Revolution 4550 scan-
ner (Vidar Corp., Herndon, VA, USA), and acquired
images were analyzed by using MicroVigene v2.9.9.9
(VigeneTech, Carlisle, MA, USA) that performed spot
finding, local background subtraction, replicate aver-
aging, and total protein normalization, producing a
single value for each sample at each end point. Statis-
tical analysis of the array data was performed by T
testing or Wilcoxon two-sample rank-sum test by
using R v2.9.2 (R Foundation for Statistical Computing,
Vienna, Austria) to compare values between groups, de-
pending on normalcy distribution values. P values < 0.05
were considered statistically significant.Immunofluorescence microscopy
Cells were cultured on cover glass in six-well plates.
After washing with PBS, cells were fixed and perme-
abilized with methanol/acetone (1:1) and blocked with
2% goat serum, 0.3% triton X-100 in PBS at room
temperature, followed by washing with PBS, and in-
cubated with an anti-HRG antibody at 4°C. After exten-
sive washings, the cells were incubated with anti-rabbit
IgG conjugated with Alexa Fluor 555 (Cell Signaling,
Danvers, MA, USA) followed by a liquid mountant
application with ProLong Gold anti-fade reagent with
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USA). A Zeiss Axio Observer was used for photographs.
Gene-expression data analysis
We compiled a collection of 4,010 breast tumor gene-
expression data derived from 23 datasets that have been
posted on the NCBI Gene Expression Omnibus (GEO)
database, as previously described [30]. In addition to the
raw expression data, we also obtained recurrence-free
survival data from a subset of the samples (n = 1,372).
HRG (NRG1) expression was measured by probe set
208231_at. We assigned each of 4,010 sample into Low
(first quartile, lowest 25%), Intermediate (second quar-
tile, intermediate 50%), and High (third quartile, highest
25%) subgroups, according to HRG expression levels,
and compared prognosis differences among these sub-
groups by using Kaplan-Meier estimates of recurrence-
free survival analysis. Furthermore, we applied HRG
expression signal as continuous variable and determined
correlation of HRG expression and risk of recurrence
among 204 HER2+ breast cancer samples, by using Cox-
regression survival analysis.
Statistical analysis
Data were expressed as means with standard error bars
included. The Student t test was used to determine statis-
tical significance between two groups. A value of P < 0.05
was considered a statistically significant difference.
Results
PI3K-pathway signaling is persistently activated in
lapatinib-resistant breast cancer cells
We used HER2+ breast cancer models of acquired thera-
peutic resistance to lapatinib established in our labora-
tory, as previously described [17,18] to investigate how,
and to what extent, deregulation of the protein signaling
network contributes to therapeutic resistance to HER2/
EGFR TKIs. As previously shown, these cells are main-
tained in 1 μM lapatinib without decreased viability,
compared with parental cell counterparts that are sensi-
tive to the antitumor effects of lapatinib (see Additional
file 2). To determine the activation state of the cell-
signaling network in lapatinib-resistant tumor cells, we
evaluated the expression of >150 protein/phosphopro-
teins representing mediators of key cell processes by
using quantitative reverse-phase protein arrays (RPMAs)
[29]. Findings from the RPMA analysis were confirmed
by Western blot analysis. For the purposes of the fol-
lowing studies, resistant cell lines were maintained in
the continuous presence of 1 μM lapatinib, even when
combined with other treatments. Consistent with our
previous findings [17], HER2 phosphorylation remained
inhibited in lapatinib-resistant cells (Figure 1A). With
this strategy, we found that the PI3K pathway remainedactivated in our models of acquired lapatinib resistance,
as indicated by the persistent phosphorylation of PI3K-
p85Y458, AktT308, mTORS2481, p70S6KS371, BadS136, and
4EBP1S65 (Figure 1A, B; see Additional file 3). In ad-
dition, protein expression of survivin, a member of the
inhibitor of apoptosis family whose downregulation in
lapatinib-treated HER2+ breast cancer cells we had pre-
viously shown to correlate with lapatinib antitumor ac-
tivity in a PI3K-dependent manner [31], remained intact
in lapatinib-resistant cells.
A PI3K-PDK1-AktT308 signaling axis maintains the survival
of lapatinib-resistant tumor cells
We used a molecular approach to knock down specific
targeted proteins in the PI3K signaling pathway to de-
termine the functional role of PI3K in maintaining the
resistant phenotype. As shown, small interfering RNA
(siRNA)-mediated knockdown of PI3K, primarily tar-
geting the p110 catalytic subunit, and triggered resistant
cells to undergo apoptosis, as indicated by increased ex-
pression of cleaved PARP and significant inhibition of
cell growth and viability (P < 0.0058) (Figure 1C, D). A
number of downstream intermediaries transduce the
PI3K signaling effects (for example, Akt, PDK1, SGK,
and PKCβ). Interestingly, phosphorylation of Akt serine
473 (S473), which is considered a hallmark of PI3K path-
way activation, was inhibited in resistant cells despite
persistent PI3K pathway activation (Figure 1A). Instead,
phosphorylation of Akt threonine 308 remained intact,
implying a role for PDK1, the kinase responsible for
phosphorylating AktT308 in resistant cells. To expand on
these findings, we individually knocked down Akt,
PDK1, SGK, and PKCβ to determine each of their effects
on the viability of resistant cells. We found that
knockdown of Akt or PDK1, but not PKCβ or SGK had
a significant antitumor effect in lapatinib-resistant cells
(Figure 2). The overlapping antitumor effects in response
to knocking down Akt or PDK1 implicated the role of a
PI3K-PDK1-AktT308 signaling axis in maintaining the
survival of lapatinib-resistant cells.
The regulation of PI3K-pathway activation and cell
survival is switched from HER2-HER3 in the treatment-na
ïve state to EGFR-HER3 signaling in lapatinib resistance
Lapatinib-naïve HER2+ breast cancer cells are addicted
to HER2 signaling. Work from our laboratory and others
has shown that regulation of prosurvival PI3K signaling
in lapatinib-resistant breast cancer cells appears to be
mediated through an HER2-independent mechanism(s)
[17,32]. Although loss of the PTEN tumor suppressor, or
the presence of PI3KCA gain-of-function mutations can
lead to constitutive activation of PI3K signaling in breast
cancer [33,34], neither was found to be relevant in our
models of resistance (data not shown). Similar to that
Figure 1 Persistent activation of PI3K signaling promotes survival in lapatinib-resistant cells. (A) pHER2, total HER2, AktT308, AktS473,
p70S6KS371, 4EBP1S65, and survivin steady-state protein expression in untreated parental BT474, BT474 treated with 0.5 μM lapatinib for 48 hours,
and rBT474 maintained in 1 μM lapatinib, as determined by Western blot analysis from whole cell extracts. (B) Phospho-PI3K protein expression
was determined by RPMA in the same treatment groups as described in (A). Results represent the mean ± standard error of triplicate samples,
and are representative of three independent experiments. *P < 0.0018. (C) Molecular knockdown of PI3K by using pooled siRNA against PI3K
subunits (*) in rBT474 cells was confirmed by Western blot analysis by using subunit-specific antibodies and an anti-PARP cleavage-product
antibody. Cells transfected with scrambled siRNA construct (NSC) served as controls. Actin steady-state protein levels served as a control to
ensure equal loading of protein. The results are representative of three independent experiments. (D) The effects of siRNA-mediated knockdown
of PI3K on rBT474 cell growth (P < 0.0058). Nonspecific siRNA construct (NSC) served as a control. Results represent the mean ± standard error of
triplicate samples, and are representative of three independent experiments.
Figure 2 A PI3K-PDK1 signaling axis mediates the effects of PI3K signaling in lapatinib-resistant cells. A comparison of the effects of
siRNA-mediated knockdown of Akt, PDK1, PKCβ, and SGK on the growth of rBT474 cells. Cells transfected with scrambled siRNA construct (NSC)
served as controls. Growth assays were performed as described in Methods. Knockdown of targeted protein was confirmed by Western blot
analysis (lower panels). Actin steady-state protein levels served as a control to ensure equal loading of protein. Results represent the mean ± standard
error of triplicate samples and are representative of three independent experiments. *P < 0.005; **P < 0.002.
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pathways previously linked to HER TKI resistance were
phosphorylated in our models of resistance (for example,
c-src, c-met) [20,35,36]; however, we were unable to
demonstrate their functional role in regulating the sur-
vival of resistant cells (see Additional files 4 and 5).
HER2-HER3 heterodimers are potent activators of
PI3K signaling [8]. HER3 was persistently phosphory-
lated on tyrosine 1197 in our models of lapatinib resis-
tance (Figure 3A) despite inactivation of its preferred
heterodimer partner HER2 (Figure 1A). HER3 knock-
down in resistant cells led to inhibition of PI3K-p85Y508
phosphorylation, increased expression of cleaved PARP,
and significant inhibition of cell growth and viability
(P < 0.013 in rSKBR3; P < 0.017 in rBT474) (Figure 3A
through D) revealing its central role in the maintenance
of cell survival in our models. Unable to detect HER4
protein in resistant cells (data not shown), we speculated
that EGFR, which is also expressed in lapatinib-resistant
cells, might be responsible for the persistent transactiva-
tion of HER3 in resistant cells. Because lapatinib is
reported to be an equipotent inhibitor of the HER2 and
EGFR kinases [14,15], we expected to find that phos-
phorylation of EGFR, similar to HER2, would be inhi-
bited in resistant cells. However, analysis of individual
EGFR phosphotyrosine sites in lapatinib-resistant cells
revealed a mixed pattern, as evidenced by variably
persistent phosphorylation of tyrosines 992 and 1148,
and marked inhibition of other phosphotyrosine sites
(Y1173, Y1068) (Figure 4).Figure 3 EGFR-HER3 transactivation regulates resistant cell survival th
on steady-state phospho-HER3Y1197 protein expression. The absolute optic
using the Odyssey Infrared Imaging System, are indicated under each corre
phosphospecific antibodies showing the effects of HER3 knockdown on EG
steady-state protein levels of cleaved PARP product, and (D) inhibition of c
P < 0.017 (rBT474); P < 0.013 (rSKBR3). Results represent the mean ± standa
independent experiments.These findings made it tempting to speculate that es-
cape from, or incomplete inhibition of EGFR tyrosine
autophosphorylation sites in response to lapatinib, over
time, led to a switch in the regulation of cell survival
from HER2-HER3-PI3K signaling in lapatinib-naive
HER2+ breast cancer cells, to EGFR-HER3-PI3K in cells
that become resistance to lapatinib. To test this hy-
pothesis, we molecularly knocked down EGFR in
lapatinib-resistant cells, which reduced HER3Y1197 phos-
phorylation and PI3K signaling, and led to increased
apoptosis (cleaved PARP) with a statistically significant re-
duction in cell viability (P < 0.018 in rBT474; P < 0.021 in
rSKBR3) (Figure 5A through C). Thus, the regulation of
HER3 phosphorylation appears to switch from HER2 in
treatment naïve cells, to EGFR in HER2+ breast cancer cell
lines that have become resistant to lapatinib.
Activation of a negative-feedback loop in resistant tumor
cells specifically dephosphorylates AktS473 despite
persistent PI3K-pathway activation
Inhibition of AktS473 phosphorylation in resistant cells
appeared inconsistent with the persistent activation of
the PI3K signaling pathway (Figure 1A). In this context,
PHLPPL (PH domain leucine-rich repeat-containing
phosphatase-like) is a protein phosphatase that is tran-
scriptionally regulated by mTORC1 [37,38]. PHLPPL
negatively feeds back on PI3K signaling by selectively
dephosphorylating Akt on S473, not T308 [37,38], ma-
king it tempting to speculate that PHLPPL might be
responsible for the pattern of Akt phosphorylationrough PI3K signaling. (A) The effects of EGFR and HER3 knockdown
al density (OD) values attributed to the p-HER3 bands, determined by
sponding lane. (B) Western blot analysis with the indicated
FRY992 and PI3K-p85Y508 in rBT474 and rSKBR3 cells. (C) Increased
ell growth in response to HER3 knockdown in rBT474 and rSKBR3 cells.
rd error of triplicate samples and are representative of three
Figure 4 Lapatinib-resistant cells exhibit a mixed pattern of EGFR tyrosine autophosphorylation. Reverse-phase protein microarray
analysis of EGFR Y992, Y1068, Y1148, and Y1173 in parental HER2+ breast cancer cell lines (BT474; SKBR3; Au565; SUM190), parental cells treated
with 1 μM lapatinib for 24 hours, and lapatinib-resistant cell counterparts (rBT474; rSKBR3; rAu565; rSUM190) maintained in 1 μM lapatinib. Results
represent the mean ± standard error of triplicate samples and are representative of three independent experiments.
Xia et al. Breast Cancer Research 2013, 15:R85 Page 7 of 15
http://breast-cancer-research.com/content/15/5/R85observed in lapatinib-resistant cells. We found that ex-
pression of PHLPPL protein was increased in resistant
cells compared with their parental cell counterparts (see
Additional file 6A). PHLPPL protein expression was de-
creased in parental cells treated with 1 μM lapatinib for
24 hours (Additional file 6A), consistent with inhibition
of PI3K-mTOR signaling in lapatinib-treated parental
cells. If the increased expression of PHLPPL in resistant
cells were related to persistent PI3K-mTOR pathway ac-
tivation, then inhibition of PI3K signaling should block
PHLPPL expression. Indeed, PHLPPL expression was
inhibited in resistant cells growing in the presence of 1
μM lapatinib, after treatment with the dual PI3K-mTOR
kinase inhibitor BEZ-NVP 235 [39] (Additional file 6A).
In addition, molecular knockdown of EGFR, which
blocked PI3K signaling, also inhibited PHLPPL protein
expression (Additional file 6B). These findings suggest that
AktS473 phosphorylation may not necessarily represent areliable pharmacodynamic readout to assess the effects of
targeted therapies on PI3K signaling.
EGFR represents an attractive target in lapatinib-resistant
HER2+ breast cancer cells
Gefitinib and erlotinib are FDA-approved EGFR TKIs
[40-42]. In our hands, when used at a final concentration
of 5 μM, neither drug was able to block persistent EGFR
tyrosine phosphorylation in lapatinib-resistant cells,
maintained in 1 μM lapatinib, nor did they restore la-
patinib sensitivity (Figure 6A, B). Neratinib, in contrast
to lapatinib, gefitinib, and erlotinib is an irreversible
EGFR and HER2 TKI [43]. Consistent with previous re-
ports [43], we found that neratinib was a potent inhibi-
tor of parental HER2+ breast cancer cells (see Additional
file 7). Neratinib, when used at higher concentrations
than in parental cell cultures, inhibited persistent phos-
phorylation of EGFR, HER3, and AktT308 in resistant
Figure 5 The effects of EGFR knockdown on steady-state levels
of the indicated proteins and phosphoproteins by using
phosphospecific antibodies. (A) Western blot analysis with the
indicated phosphospecific antibodies showing the effects of EGFR
knockdown on EGFRY992, PI3K-p85Y508, and AktT308 in rBT474 and
rSKBR3 cells. (B) Western blot analysis of cleaved PARP product in
rBT474 and rSKBR3 cells transfected with EGFR siRNA. Scrambled
siRNA sequences (NSC) served as controls. Steady-state actin protein
served as a control for equal loading of protein. Western blot
data shown in A and B are representative of three independent
experiments. (C) Effects of siRNA-mediated knockdown of EGFR
on tumor cell growth in rBT474 and rSKBR3 cell lines. Results
represent the mean ± standard error of triplicate samples and are
representative of three independent experiments. P < 0.018 (rBT474)
and P < 0.021 (rSKBR3).
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and inhibition of cell growth and viability (P < 0.0008 in
rSKBR3; P < 0.0025 in rBT474) (Figure 6A, B). These
findings suggest that persistent EGFR signaling, rather
than incomplete inhibition HER2, can play a role in main-
taining the lapatinib-resistant phenotype.
Autoinduction of heregulin in resistant cells drives the
EGFR-HER3-PI3K signaling axis
We next sought to identify an underlying driver respon-
sible for the persistent activation of the HER3-EGFR-PI3K
signaling axis in lapatinib-resistant HER2+ breast cancer
cells. Previous work from our laboratory had shown thatheregulin β1 (HRG), a soluble ligand for HER3 and HER4,
but not an EGFR ligand (EGF), can abrogate the inhibitory
effects of lapatinib on cell-signaling pathways in parental
HER2+ breast cancer cells [44,45], findings that were re-
cently confirmed by Settleman and colleagues [46]. We
therefore speculated that autocrine induction of HRG
might play a role in the development of lapatinib resis-
tance by providing the HER3 activation input, which, in
conjunction with concomitant persistent EGFR activation,
results in the formation of HER3-EGFR heterodimers. As
shown, HRG protein expression was indeed increased in
lapatinib-resistant cells compared with parental cell coun-
terparts (Figure 7A, B). In contrast, we did not find in-
creased expression of EGF ligands (data not shown).
Interestingly, we found the 105-kDa membrane-bound
species (Figure 6B, labeled HRG1), which can activate
HER3 [47], to be the predominant form of HRG increased
in resistant cells. Moreover, protein expression of the
40-kDa soluble form of HRG was decreased in resistant
cells compared with parental cell counterparts (Figure 7B,
labeled HRG2). Importantly, targeted molecular knock-
down of HRG in resistant cells induced apoptosis (cleaved
PARP) and decreased cell growth and viability (P < 0.009
in rSKBR3; P < 0.0023 in rAu565) (Figure 7C, D).
We next sought to gain a better understanding of
the mechanism underlying the increased expression of
membrane-bound HRG in resistant cells. Based on RT-
PCR analysis, increased HRG resistant cells did not ap-
pear to be transcriptionally mediated (data not shown).
ADAM17 is a metallopeptidase that proteolytically pro-
cesses the 105-kDa membrane-bound form to smaller-
molecular-weight soluble forms of HRG [48]. A previous
report suggested that transient inhibition of Akt phos-
phorylation in trastuzumab-treated HER2+ breast cancer
cells can lead to increased expression of ADAM17 and
consequently increased expression of the lower-molecu-
lar-weight (40 kDa) soluble form of HRG [49]. In contrast,
here we showed that the major forms of ADAM17 were
inhibited over time in lapatinib-treated parental HER2+
breast cancer cell lines (Figure 7E, compare 1-hour and
24-hour treatments). Furthermore, ADAM17 was mark-
edly reduced in lapatinib-resistant cells compared with
their untreated parental cell counterparts. These findings
made it tempting to speculate that inhibition of ADAM17
by lapatinib blocks proteolytic processing of the 105-kDa
membrane-bound form of HRG, leading to its increased
expression and concomitant decreased expression of
lower-molecular-weight forms in resistant cells.
Increased HRG expression predicts a poor outcome in
HER2+ breast cancer patients
To shed light on the potential clinical implications of the
autocrine induction of HRG in lapatinib-resistant HER2+
breast cancer cells, we analyzed the relation between HRG
Figure 6 Gefitinib and erlotinib do not reverse lapatinib resistance. (A) Cell growth of rBT474 and rSKBR3 cells after treatment with 5 μM
gefitinib or erlotinib or 1 μM or 5 μM neratinib for 72 hours. Resistant cells were maintained in the presence of 1 μM lapatinib. Results represent
the mean ± standard error of triplicate samples, and are representative of three independent experiments. P < 0.0025 (rBT474) and P < 0.0008
(rSKBR3). (B) Western blot analysis showing steady-state pEGFRY992, pHER3Y1197, pAktY308 phosphoprotein and cleaved PARP product expression
in rBT474 and rSKBR3 cells after 72 hours of treatment with 5 μM gefitinib, erlotinib, or neratinib (1 and 5 μM), or vehicle (0.01% DMSO) alone.
Steady-state actin protein levels served as a control for equal loading of protein. The results are representative of three independent experiments.
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HER2+ breast cancer. Our analysis of the relation between
HRG gene expression and clinical outcome in women with
HER2+ breast cancer (n = 204) revealed a linear cor-
relation between HRG expression and risk of recurrence
(P = 0.0036, Cox-regression analysis) and a statistically
significant difference (P = 0.0034, Kaplan-Meier Estimates
survival analysis) between high HRG expression and de-
creased recurrence-free survival (RFS) (Figure 8). Median
RFS in tumors with high expression and others (Inter-
mediate plus Low) was 2.84 and 10.04 years, respectively.
By using clinical parameters that were associated with
clinical outcome, such as tumor size, grade, nodal status,
HER2, ER, and PR status, we found that expressions of
HRG was independently poor prognosis factor (comparing
HRG high, intermediate, and low expression groups,
P = 0.049, n = 581, COXPH survival analysis). Thus,
autoinduction of HRG in lapatinib-resistant tumors
could potentially contribute to a more-aggressive tumor
phenotype with a poorer clinical outcome.
Discussion
The robustness of a biologic system can be defined by
its ability to maintain function when perturbed [50]. Ac-
cordingly, loss of HER2 signaling represents a significant
perturbation to HER2-addicted breast cancer cells. Pre-
vious work from our laboratory and others has shownthat the antitumor activity of lapatinib tracks with its
ability to inhibit HER2 signaling [31,51]. Prolonged ex-
posure to lapatinib, however, leads to the development
of acquired therapeutic resistance in models of HER2+
breast cancer and in patients. We and others have
shown that resistance to lapatinib does not appear to be
mediated by reactivation of HER2 [17,23,32]. Instead, we
now show that an autocrine feedback mechanism invol-
ving membrane-bound HRG can promote a previously
unsuspected EGFR-HER3-PI3K-PDK1 signaling axis that
is resistant to the effects of lapatinib and other FDA-
approved EGFR TKIs. A key finding here is that the un-
opposed action of EGFR, which is incompletely inhibited
by lapatinib, can transactivate HER3 in a manner driven
by autocrine HRG. These findings demonstrate the ro-
bustness of the HER receptor-ligand system that enables
HER2+ breast cancer cells to survive loss of HER2 sig-
naling without the need to invoke mutations in the
target kinase or its downstream intermediaries, or the
activation of redundant signaling pathways.
In contrast to HRG, we were unable to demonstrate
increased expression of EGFR ligands (for example, EGF
betacellulin) in our models of lapatinib resistance. It is
intriguing to speculate that the preferential induction of
HRG reflects the drive of the tumor cell to maintain
PI3K pathway activation in response to the loss of the
HER2-HER3 oncogenic signaling complex, which is a
Figure 7 Autocrine induction of HRG drives survival of resistant cells. (A) Immunofluorescence microscopy of HRG expression in the
indicated cell lines by using a primary rabbit anti-HRG antibody and visualized with an anti-rabbit IgG Alexa Fluor 555 (red) conjugated secondary
antibody. Cell nuclei were visualized by DAPI staining (blue). These results are representative of other fields on the slide. (B) Western blot analysis
of HRG type 1 (115 kDa) and type 2 (40 kDa) steady-state protein levels in lapatinib-resistant (rSKBR3; rAu565; rBT474) maintained in 1 μM
lapatinib, and untreated parental cell counterparts (SKBR3; BT474; Au565); actin served as a control for equal loading of protein. (C) Western blot
analysis of survivin and cleaved PARP product after HRG knockdown in rAu565 and rSKBR3 cells. Cells transfected with scrambled siRNA construct
(NSC) served as controls. Actin served as a control for equal loading of protein. (D) Effects of siRNA-mediated knockdown of HRG on tumor cell
growth in rAu565 and rSKBR3 cell lines. Results represent the mean ± standard error of triplicate samples, and are representative of three
independent experiments. P < 0.009 (rSKBR3) and P < 0.0023 (rAu565). (E) Western blot analysis of ADAM17 protein level in parental BT474 and
SKBR3 ± lapatinib treatment as indicated in the figure. Resistant cells (rBT474 and rSKBR3) were growing in the presence of 1 μM lapatinib. Hela
cell extract was used as a positive control. Two bands from 75 kDa to 100 kDa can be detected by a specific ADAM17 antibody. These results are
representative of three independent experiments.
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could have led to the formation of EGFR homodimers,
which are less-potent activators of PI3K signaling com-
pared with HER3-containing dimers. Indeed, lapatinib-
resistant cells may also be primed to respond to HRG
stimulation, as HER3, the cognate receptor for HRG, has
been shown to be upregulated in HER2+ breast cancer
models of acquired lapatinib resistance [21].
The mechanism involved in the autoinduction of HRG
in resistant cells described here differs from the transient
activation of HRG previously reported in trastuzumab-
treated cells [49]. First, activation of HRG by trastuzumabwas not shown to be directly linked to the development of
acquired therapeutic resistance to trastuzumab. Second,
induction of HRG in trastuzumab-treated cells was re-
portedly mediated by activation of ADAM17. In contrast,
we showed that lapatinib inhibits expression of ADAM17,
which may explain the increased expression of full-length
membrane-bound HRG with a concomitant decrease in
the expression of the lower-molecular-weight forms. Al-
though lapatinib and trastuzumab both target HER2,
our findings further underscore the distinct biologic ef-
fects that each can have on HER2+ targeted breast can-
cer cells.
Figure 8 Recurrence-free survival in HER2+ breast cancer
patients according to HRG expression levels. Tick marks in
Kaplan-Meier estimates of recurrence-free survival indicate patients
whose data were censored by the time of last follow-up or owing to
death. P < 0.0034 was calculated by using log-rank Mantel-Cox test.
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the cell context in the interpretation of predictive or cor-
relative biologic readouts. For example, we previously
reported that the phosphorylation state of HER3 could
discriminate those patients with HER2+ inflammatory
breast cancers who were more likely to respond to la-
patinib monotherapy [16]. In that lapatinib-naïve setting,
HER3 was likely transactivated by HER2 and therefore
more sensitive to the antitumor activity of a potent
HER2 tyrosine kinase inhibitor such as lapatinib. How-
ever, in HER2+ breast cancer cells that have become
resistant to lapatinib, HER3 phosphorylation can be reg-
ulated by EGFR-HER3 dimers, which were not res-
ponsive to inhibition by lapatinib or other EGFR TKIs.
Thus, monitoring tumors for the presence of increased
HER3 phosphorylation, and perhaps phosphorylated
EGFR, during lapatinib treatment may be an effective
biomarker to identify patients whose tumors are be-
coming HRG-rewired. In addition, phosphorylation of
AktS473, which has long been considered a hallmark of
PI3K pathway activation, was inhibited in lapatinib-
resistant cells despite persistent activation of the PI3K
pathway. An explanation for this apparent discrepancy
can be attributed to the increased expression of a PI3K-
mTOR regulated phosphatase (PHLPPL) that dephos-
phorylates Akt on S473, in lapatinib-resistant cells
(Additional file 6A). Thus, the predictive power of bio-
markers such as phosphorylated HER3 or phospho-
AktS473 would need to be placed into the context of the
signals regulating its activation for clinical imple-
mentation. Consequently, clinical confirmation of the
predictive nature of the elucidated pathway biomarker
architecture would have to take place within that same
context: in this instance tumor tissue from patients who
relapsed after initially responding to lapatinib therapyand not from more easily obtained pretreatment biopsy
samples. Our findings provide the scientific rationale
to collect these tumor specimens so that validation of
biomarkers of acquired resistance could be rigorously
interrogated.
We previously showed that the antitumor activity of
lapatinib in HER2+ breast cancer cells was not affected
by EGF stimulation [44]. Here, however, increased ex-
pression of HRG can not only promote acquired thera-
peutic resistance to HER TKIs, but it also can mediate
primary resistance to lapatinib (see Additional file 8)
[44-46]. The frequent expression of HRG in solid tumors
[52], including triple-negative breast cancers, may pro-
vide an explanation as to why current FDA-approved
HER TKIs have had limited clinical impact in the treat-
ment of the majority of HER2-overexpressing and EGFR-
expressing solid tumors, with the exception of head and
neck cancers [53]. Importantly, we identified HRG expres-
sion as an independent negative predictor of clinical out-
come in patients with HER2+ breast cancers (Figure 8).
Thus, targeting ligand-mediated feedback loops represents
a new treatment strategy to overcome therapeutic resis-
tance established through this mechanism.
Although current FDA-approved EGFR TKIs did not
suppress HRG-driven EGFR activation in our models of
resistance, siRNA-mediated knockdown of EGFR and
treatment with the irreversible pan-HER TKI neratinib
exerted antitumor effects in resistant cells (Figure 6A, B).
Furthermore, whereas HRG can reverse the antitumor ef-
fects of lapatinib in parental HER2+ breast cancer cells
(Additional file 8) [44-46], the antitumor effects of nera-
tinib in parental HER2+ breast cancer cells are more re-
sistant to HRG (Additional file 8). These findings are
consistent with the ability of neratinib to exert antitumor
effects on HRG-expressing resistant cells. Although nera-
tinib is described as a pan-HER inhibitor, at clinically re-
levant concentrations, it can affect non-HER receptor
kinases that contain homologous ATP kinase domains.
Whereas lapatinib has been shown to be a highly specific
TKI for HER2 and EGFR, neratinib and many other
FDA-approved TKIs exhibit promiscuous inhibitory ef-
fects on non-HER kinases at clinically relevant concentra-
tions [54]. These effects may contribute to the antitumor
effects of neratinib in resistant cells, particularly at higher
concentrations. Indeed, preliminary clinical data indicate
that neratinib remains clinically active in the treatment of
HER2+ breast cancers that have progressed on prior
lapatinib-based therapy (Chow L, et al. Efficacy and safety
of neratinib (HKI-272) in combination with paclitaxel in
HER2+ metastatic breast cancer. San Antonio Breast Can-
cer Symposium, 2010). Furthermore, it is not surprising
that parental HER2+ breast cancer cells were more sensi-
tive to the antitumor effects of neratinib compared with
lapatinib-resistant cells. Resistance to HER2 TKIs does
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as we and others have shown [17-23,55,56]. Therefore,
completely reversing established resistance will likely re-
quire more than a single targeted intervention (for exam-
ple, neratinib). It will require a combination approach,
which, based on the findings reported here, should include
inhibitors that block HRG-HER3-EGFR-PI3K-PDK1 sig-
naling. These findings suggest that inhibition of wild-type
EGFR remains an attractive therapeutic strategy awaiting
the development of more-effective EGFR inhibitors.
The findings presented here have broad implications
for the development of TKIs used to treat cancer and
other kinase-driven diseases. As we have demonstrated,
selection of clinical candidates based on activity profiles
from in vitro kinase assays can be misleading. To the ex-
tent that lapatinib, erlotinib, and gefitinib are considered
potent EGFR kinase inhibitors, none was able to neu-
tralize HRG-mediated activation of EGFR. In contrast,
neratinib appears to be a more-effective inhibitor of
EGFR phosphorylation and activation, even in the pre-
sence of HRG in resistant and parental cells. It is
tempting to suggest that the use of PI3K or mTOR se-
lective inhibitors will prevent the development of ligand-
mediated resistance. However, given the complex feed-
back mechanisms that govern these cytoplasmic signaling
events, and the potential for HRG to exert promiscuous
effects on cell-signaling pathways in a PI3K-independent
manner [57], combination therapies that target both pro-
ximal and distal signaling are more likely to yield better
clinical outcomes. Progressing TKIs into the clinic, based
on their ability to inhibit multiple tyrosine autophos-
phorylation sites, may lead to the identification of
more-effective drugs with a reduced risk of developing
therapeutic resistance, and better candidates for perso-
nalized, combination therapies.
Conclusions
Molecular targeted therapies that are directed against
tyrosine kinases and receptor tyrosine kinases represent
an important class of cancer drugs. However, development
of TKI resistance remains a significant clinical dilemma
that has limited the clinical impact of this class of targeted
drugs in a broad range of solid tumors against which they
were predicted to be effective. Past descriptions of mecha-
nisms of TKI resistance have been attributed to mutations
in targeted kinases or compensatory activation of signaling
pathways that circumvent the target. Here we demon-
strated the robustness of the HER biologic system to re-
spond to a significant perturbation in cell signaling in the
context of describing an entirely new mechanism of resis-
tance to HER TKIs, including the FDA-approved dual
HER2/EGFR TKI lapatinib, which is triggered by auto-
crine induction of the HER3 ligand, heregulin β1 (HRG).
Whereas lapatinib, a supposed equipotent HER2 andEGFR kinase inhibitor, based on data from in vitro kinase
assays, appropriately inhibited HER2 signaling, EGFR con-
versely was incompletely inactivated. Persistent EGFR
signaling, coupled with the autocrine induction of mem-
brane-bound HRG, contributed to a switch in the
regulation of cell survival from HER2-HER3-PI3K in
treatment-naïve HER2+ breast cancer cells to an HRG-
driven EGFR-HER3-PI3K-PDK1 signaling axis in lapatinib-
resistant tumor cells. Importantly, the FDA-approved
EGFR TKIs gefitinib and erlotinib failed to block EGFR
signaling and restore lapatinib sensitivity. Wild-type EGFR
did, however, remain an attractive target, as molecular
knockdown of EGFR and treatment with the irreversible
pan-HER TKI neratinib blocked residual EGFR signaling,
exerting an antitumor effect in resistant cells.
We further showed the clinical relevance of increased
HRG expression in TKI-resistant tumor cells in a large
breast cancer dataset (n = 204) of women with HER2+
breast cancers where increased HRG expression was an
independent predictor for a significantly poorer clinical
outcome (recurrence-free survival) compared with women
whose tumors expressed moderate to low levels of HRG
(P < 0.0036). Thus, incomplete inhibition and persistent
signaling of the target itself, driven by a ligand-mediated
autocrine feedback loop, may have broad implications for
the treatment of diseases by using TKI therapies. These
findings underscore potential inadequacies associated with
the current approach of selecting clinical TKI candidates
based on activity profiles from in vitro kinase assays. If in-
complete target inhibition driven by autocrine ligand in-
duction can mediate resistance to a selective inhibitor,
such as lapatinib, then induction of ligand-driven auto-
crine feedback loops in response to promiscuous kinase
inhibitors may be a new major causal factor of resistance.
Selecting clinical lead candidates based on their ability to
inhibit multiple tyrosine autophosphorylation sites instead
of inhibition from in vitro kinase assays may lead to the
identification of more-effective drugs with a reduced risk
of developing therapeutic resistance.Additional files
Additional file 1: List of antibodies used in the RPMA analysis.
Additional file 2: Lapatinib-resistant cells remain viable in
concentrations of lapatinib lethal to parental cells. Cell growth and
viability in parental cells (BT474; SKBR3) treated with 1 μM lapatinib for 72
hours, compared with resistant cells (rBT474; rSKBR3) continuously
cultured in the presence of 1 μM lapatinib. Parental cells treated with
vehicle alone (0.01% DMSO) served as controls. Results represent the
mean ± standard error of triplicate samples, and are representative of
three independent experiments.
Additional file 3: Persistent PI3K signaling in lapatinib-resistant
cells. Reverse-phase protein microarray analysis of the indicated
phosphorylated proteins by using the indicated phosphotyrosine-specific
antibodies. Results represent the mean ± standard error of triplicate
samples and are representative of three independent experiments.
Xia et al. Breast Cancer Research 2013, 15:R85 Page 13 of 15
http://breast-cancer-research.com/content/15/5/R85Additional file 4: Inhibition of c-src does not reverse lapatinib
resistance. Treatment of rBT474 and rSKBR3 with a specific src inhibitor
(AZD0530) had relatively little effect on cell growth. Top panels show the
activation of Src in rBT474 and rSKBR3 compared with parental cells after
treatment with 1 μM lapatinib for 24 hours, as demonstrated by Western
blotting, by using a phosphospecific antibody to srcY416. Actin steady-
state protein served as a control for equal loading of protein. The middle
panels demonstrate inhibition of srcY416 by a specific src kinase inhibitor
AZD0530, used at 10 μM for 72 hours, and the lower bar graph shows
the effects of AZD0530 on the growth of rBT474 and rSKBR3 cells.
Resistant cells were maintained in the presence of 1 μM lapatinib. Results
represent the mean ± standard error of triplicate samples, and are
representative of three independent experiments.
Additional file 5: Inhibition of c-met does not reverse lapatinib
resistance. rBT474 and rSKBR3 cells were treated with a selective
c-met inhibitor, SU11274 at 10 μM for 72 hours and then analyzed for
cell viability and proliferation. Resistant cells were maintained in the
presence of 1 μM lapatinib. Results represent the mean ± standard error of
triplicate samples, and are representative of three independent experiments.
Additional file 6: EGFR knockdown and inhibition of PI3K/mTOR
signaling block PHLPPL2 protein expression. (A) The effects of
EGFR knockdown on steady-state levels of the indicated proteins/
phosphoproteins was determined by using specific primary antibodies
(see Methods). The absolute optical density (OD) values attributed to the
PHLPPL2 protein, determined by using the Odyssey Infrared Imaging
System, are indicated under each corresponding lane. (B) Inhibition of
PI3K/mTOR signaling blocks PHLPPL2 protein expression. The effects of
0.2 μM NVP-BEZ 235 for 48 hours on the expression of PHLPPL2 protein
in rBT474 and rSKBR3 cells, as determined by Western blot. Actin protein
levels served as a control to ensure equal loading of protein. Resistant
cells were maintained in the presence of 1 μM lapatinib. Parental cells
(BT474; SKBR3) were treated with 1 μM lapatinib for 24 hours. Results are
representative of three independent experiments.
Additional file 7: Sensitivity of parental HER2+ breast cancer cells line
to neratinib. Parental BT474 and SKBR3 were treated with neratinib at the
indicated concentrations (0.1; 0.5; 1; 5 μM) for 72 hours, and then growth and
viability were determined. Results represent the mean ± standard error of
triplicate samples, and are representative of three independent experiments.
Additional file 8: HRG reverses the antitumor effects of lapatinib,
but not neratinib, in parental HER2+ breast cancer cells. Cell growth
and viability was assessed in parental BT474 cells treated with 1 μM
lapatinib or neratinib in the presence or absence of HRG (50 ng/ml) for
72 hours. Cells treated with vehicle alone (0.01% DMSO) served as
controls. Results represent the mean ± standard error of triplicate
samples, and are representative of three independent experiments.
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